| Entry |
|
|---|
| Name |
Teduglutide (USAN/INN);
Teduglutide (genetical recombination) (JAN);
Gattex (TN);
Revestive (TN)
|
|---|
| Product |
|
|---|
| Formula |
C164H252N44O55S
|
|---|
| Exact mass |
3749.7995
|
|---|
| Mol weight |
3752.0825
|
|---|
| Sequence |
His Gly Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
Asp |
|---|
| Type |
Peptide |
|---|
| Remark |
|
|---|
| Efficacy |
Mucosal growth promotor, Glucagon-like peptide 2 receptor agonist |
|---|
| Disease |
Short bowel syndrome [DS: H01469] |
|---|
| Comment |
GLP-2 [HSA: 9340] [KO: K04582] analog
Treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease
|
|---|
| Target |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AX Various alimentary tract and metabolism products
A16AX08 Teduglutide
D06053 Teduglutide (USAN/INN) <US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Gastrointestinal Agents, Other
Short Bowel Syndrome Agents
Teduglutide
D06053 Teduglutide (USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP2R
D06053 Teduglutide (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06053
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06053
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06053
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
